

1. Record Nr.	UNINA9910461459703321
Autore	Corey Elizabeth
Titolo	An Iowa schoolma'am [[electronic resource]] : letters of Elizabeth "Bess" Corey, 1904-1908 / / edited by Philip L. Gerber and Charlotte M. Wright ; foreword by Paul Theobald
Pubbl/distr/stampa	Iowa City, : University of Iowa Press, c2011
ISBN	1-58729-961-5
Descrizione fisica	1 online resource (226 p.)
Collana	A bur oak book
Altri autori (Persone)	GerberPhilip L WrightCharlotte M TheobaldPaul
Disciplina	371.10092 B
Soggetti	Teachers - Iowa Rural schools - Iowa Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"A Bur Oak book."
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Editor's note / by Charlotte M. Wright -- Letters from Corey Farm, October 1904 -- Letters from Walnut, November 1904 to February 1905 -- Letters from Harlan, June 1905 to August 1905 -- Letters from Tenant, September 1905 to June 1906 -- Letters from Harlan, June 1906 to July 1906 -- Letters from Irwin, January 1908 to June 1908 -- Letters from Corey Farm and Harlan, July 1908 to August 1908.
Sommario/riassunto	Readers everywhere fell for Elizabeth Corey, the irrepressible, independent, and fearless Bachelor Bess, whose letters home to Iowa gave us a firsthand account of her adventures on a South Dakota homestead from 1909 to 1919. Now, through the letters she wrote home between 1904 and 1908, readers can make the acquaintance of a younger Bess facing the realities of life in an Iowa country school system with energy, enthusiasm, and ambition. Sixteen-year-old Bess wrote her early letters when she was away from the family farm, trying to complete the ninth

2. Record Nr.	UNINA9910300201603321
Titolo	Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development : A Focus on Early Phase Clinical Studies // edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch
Pubbl/distr/stampa	London : , : Springer London : , : Imprint : Springer, , 2015
ISBN	1-4471-4920-3
Edizione	[1st ed. 2015.]
Descrizione fisica	1 online resource (316 p.)
Disciplina	610 615 615.19 616 616.39 616.46 616462
Soggetti	Medicine Internal medicine Diabetes Metabolism - Disorders Pharmacology Pharmaceutical technology Medicine/Public Health, general Internal Medicine Metabolic Diseases Pharmacology/Toxicology Pharmaceutical Sciences/Technology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4.

Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9. Assessment of cardiovascular safety of new diabetes drugs.

Sommario/riassunto

This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. *Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development* will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.